This is a mechanism module, not a specific disease, and NOT a general representation of every kind of cyst. It is a pathological structure-formation ("Xogenesis") module. Xogenesis anchor: the terminal output is a cyst (MPATH:62), an OGMS:0000078 pathological anatomical structure produced by an OGMS:0000080 pathological transformation (a canonical tubule segment becomes a cyst); process genus OGMS:0000061 pathological bodily process; site UBERON:0002113 kidney. SNOMED "Morphologically abnormal structure" (49755003) is an external census/gap guide only and is not bound here. It models epithelial (tubular) renal cystogenesis, the cAMP-driven ciliopathy/PKD pathway; it deliberately does not cover mechanistically unrelated cysts (arachnoid, dermoid, parasitic hydatid, neoplastic cystadenoma, developmental cavitation), which share no common trigger-to-effector chain. Disorder entries reference individual nodes via conforms_to (e.g., "renal_cystogenesis#Cyst-Lining Epithelial Proliferation and Transepithelial Fluid Secretion"). The module defines the expected pathophysiology structure; conforming nodes in disorder files should include the corresponding cell types, biological processes, and causal edges, specialized to their disease context. Key disease-specific substitutions: ADPKD substitutes germline PKD1/PKD2 (polycystin) loss with a somatic second-hit; ARPKD substitutes PKHD1/fibrocystin at the ciliary trigger; nephronophthisis substitutes NPHP-gene transition-zone defects; syndromic ciliopathies substitute BBSome/IFT lesions and also conform to ciliopathy_dysfunction for their multisystem features. Autosomal Dominant Polycystic Kidney Disease is the flagship worked conformer, declaring conforms_to across all five module nodes; the general Polycystic Kidney Disease entry conforms at the cAMP/V2R and proliferation/secretion nodes. This module is the cystogenic-machinery complement of ciliopathy_dysfunction, which captures the broader Hedgehog/PCP developmental arm of the ciliopathies but not the cAMP-CFTR cyst-fluid pathway detailed here. Modules bind GO and CL terms only and do not use chemical (CHEBI) or disease (MONDO) term bindings; drug and solute chemistry is described in prose, except in the treatments block where the therapeutic agent carries a CHEBI identifier per the treatment schema.
Polycystin and Primary Cilium Signaling Loss
trigger
The shared upstream lesion of the inherited cystic kidney diseases. The polycystin-1/polycystin-2 complex and other ciliary and basal-body proteins localize to the primary cilium of renal tubular epithelial cells, where they act as a flow sensor that governs intracellular calcium. Loss-of-function mutations (or, in ADPKD, a germline mutation plus a somatic second hit) abolish this mechanosensitive calcium signal, leaving the cell unable to read the mechanical cues that normally maintain tubular architecture and restrain proliferation. The specific ciliary or polycystin lesion differs by disorder but the loss of the cilium-dependent calcium restraint is shared.
Downstream
-
cAMP and Vasopressin-V2R Signaling Activation
Show evidence (2 references)
"Loss or dysfunction of PC1 or PC2 may therefore lead to PKD owing to the inability of cells to sense mechanical cues that normally regulate tissue morphogenesis."
Establishes that polycystin-1/polycystin-2 mediate flow sensation in the primary cilium of renal epithelium and that their loss causes PKD by abolishing the mechanosensitive signal, the trigger of this module. Evidence source is IN_VITRO because the flow-induced calcium response was measured in isolated renal epithelial cells and antibody-blocked wild-type cells.
"Dysregulation of these pathways due to genetic mutations in PKD1 and PKD2 leads to disrupted Ca+2 and cAMP signaling, aberrant fluid secretion, and uncontrolled cellular proliferation, resulting in tubular cystogenesis."
Directly connects PKD1/PKD2 ciliary-signaling dysregulation to disrupted calcium and cAMP signaling, fluid secretion, and proliferation that converge on tubular cystogenesis, framing the whole module chain. Evidence source is OTHER because this is a review.
cAMP and Vasopressin-V2R Signaling Activation
amplifier
The amplifying step and the principal therapeutic target. The fall in intracellular calcium that follows polycystin/ciliary loss disinhibits calcium-inhibitable adenylate cyclase and reduces cAMP degradation, raising intracellular cAMP in tubular epithelial cells. This elevation is further driven by abnormal stimulation of the Gs-coupled vasopressin V2 receptor (V2R) in the collecting duct, which activates adenylate cyclase. cAMP therefore accumulates in the mutant epithelium and becomes the central second messenger that converts the upstream signaling defect into the two cystogenic outputs (proliferation and fluid secretion). Because the V2R sits upstream of this node, pharmacological V2R blockade lowers cystic-tissue cAMP and is the basis of tolvaptan therapy.
Downstream
-
Cyst-Lining Epithelial Proliferation and Transepithelial Fluid Secretion
Show evidence (2 references)
"Increased levels of cAMP in tubular cells, reflecting modifications in intracellular calcium homeostasis and abnormal stimulation of the vasopressin V2 receptor (V2R), play a central role in cystogenesis."
Establishes elevated tubular-cell cAMP, driven by disrupted calcium homeostasis and abnormal V2R stimulation, as central to cystogenesis, the amplifier step of this module. Evidence source is OTHER because this is a review.
"The whole secretory process is stimulated by increased levels of cAMP in the cells, probably reflecting modifications in the intracellular calcium homeostasis and abnormal stimulation of the vasopressin V2 receptor."
Documents that the cyst-fluid secretory process is stimulated by raised cAMP arising from disturbed calcium homeostasis and V2R stimulation, linking this amplifier to the downstream secretion effector. Evidence source is OTHER because this is a review.
Cyst-Lining Epithelial Proliferation and Transepithelial Fluid Secretion
central effector
The rate-limiting central effector where the conserved cystogenic engine runs. Elevated cAMP acts on the calcium-depleted mutant epithelium in two complementary ways. First, it becomes mitogenic: through cross-talk to the B-Raf/MEK/ERK pathway that is normally repressed in healthy tubular cells, cAMP stimulates proliferation of the mural cyst-lining epithelium. Second, it drives cAMP-dependent transepithelial chloride secretion through the apical CFTR chloride channel, and the secreted chloride osmotically pulls fluid into the tubular lumen. Proliferation expands the cyst wall while fluid secretion fills the cavity; together they are the pivotal, disorder-agnostic step that converts a normal tubule segment into a growing cyst. This is the key conformance target of the module.
Downstream
-
Progressive Cyst Expansion and Kidney Enlargement
Show evidence (2 references)
"Progressive enlargement of the kidneys is due to aberrant proliferation of the cyst epithelial cells, together with accumulation of fluid within the cyst cavities due to transepithelial fluid secretion."
Directly identifies aberrant cyst-lining epithelial proliferation plus transepithelial fluid secretion as the paired cystogenic mechanisms, the central effector of this module. Evidence source is OTHER because this is a review.
"Fluid secretion by cystic cells is driven by cAMP-dependent transepithelial Cl(-) secretion involving apical cystic fibrosis transmembrane conductance regulator (CFTR) Cl(-) channels."
Establishes that cyst fluid secretion is cAMP-dependent chloride secretion through apical CFTR channels, the secretory arm of this central effector. Evidence source is OTHER because this is a review.
Progressive Cyst Expansion and Kidney Enlargement
effector
Sustained proliferation and continued cAMP-driven fluid secretion enlarge individual cysts, which progressively detach from the parent nephron and behave as isolated fluid-filled sacs that keep secreting into a closed lumen. As hundreds to thousands of cysts expand, total kidney volume rises relentlessly, producing the massively enlarged polycystic kidneys that are the radiological hallmark and the best early biomarker of disease progression. This is the effector step that converts the microscopic cystogenic process into the gross organ phenotype.
Downstream
-
Nephron Loss and Progressive Kidney Failure
Show evidence (2 references)
"In ADPKD, Cl secretion plays a central role in the accumulation of cyst fluid and the remarkable size of the cystic kidneys."
Directly attributes cyst-fluid accumulation and the remarkable size of the cystic kidneys to chloride secretion, supporting cyst expansion and kidney enlargement as the effector step. Evidence source is OTHER because this is a review.
"Progressive enlargement of the kidneys is due to aberrant proliferation of the cyst epithelial cells, together with accumulation of fluid within the cyst cavities due to transepithelial fluid secretion."
Confirms that progressive kidney enlargement is the organ-level result of cyst-lining proliferation and fluid accumulation, the effector consequence of the central cystogenic engine. Evidence source is OTHER because this is a review.
Nephron Loss and Progressive Kidney Failure
consequence
The clinical end state of the module. Expanding cysts compress adjacent functioning nephrons and the renal vasculature, and the cystic microenvironment provokes interstitial inflammation and progressive fibrosis of the intervening parenchyma. The cumulative loss of functioning nephrons erodes glomerular filtration over decades, so that despite compensatory hyperfiltration the kidney function declines and a substantial fraction of patients reach end-stage kidney disease. This is the consequence of the conserved polycystin/cilia-loss to cAMP to proliferation-and-secretion to cyst-expansion chain.
Show evidence (2 references)
"Polycystic kidney disease (PKD) is the most common hereditary disorder that disrupts renal function and frequently progresses to end-stage renal disease."
Establishes progression to end-stage renal disease as the clinical consequence of polycystic kidney disease, the terminal node of this module. Evidence source is OTHER because this is a review.
"Autosomal dominant polycystic kidney disease is the most prevalent, potentially lethal, monogenic disorder."
Frames ADPKD, the prototypical cystogenesis disorder, as a prevalent and potentially lethal monogenic disease, supporting the severity of this consequence node. Evidence source is OTHER because this is a review.